SI2513093T1 - Novi CCR2 receptorski antagonisti in njihove uporabe - Google Patents
Novi CCR2 receptorski antagonisti in njihove uporabeInfo
- Publication number
- SI2513093T1 SI2513093T1 SI201030770T SI201030770T SI2513093T1 SI 2513093 T1 SI2513093 T1 SI 2513093T1 SI 201030770 T SI201030770 T SI 201030770T SI 201030770 T SI201030770 T SI 201030770T SI 2513093 T1 SI2513093 T1 SI 2513093T1
- Authority
- SI
- Slovenia
- Prior art keywords
- receptor antagonists
- ccr2 receptor
- new ccr2
- new
- antagonists
- Prior art date
Links
- 102000004497 CCR2 Receptors Human genes 0.000 title 1
- 108010017312 CCR2 Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179555 | 2009-12-17 | ||
| EP10162621 | 2010-05-12 | ||
| PCT/EP2010/069549 WO2011073154A1 (en) | 2009-12-17 | 2010-12-13 | New ccr2 receptor antagonists and uses thereof |
| EP10796336.5A EP2513093B1 (en) | 2009-12-17 | 2010-12-13 | New ccr2 receptor antagonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2513093T1 true SI2513093T1 (sl) | 2014-11-28 |
Family
ID=43533115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201030770T SI2513093T1 (sl) | 2009-12-17 | 2010-12-13 | Novi CCR2 receptorski antagonisti in njihove uporabe |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US8765949B2 (sl) |
| EP (3) | EP2813503B1 (sl) |
| JP (1) | JP5632014B2 (sl) |
| KR (1) | KR101530234B1 (sl) |
| CN (1) | CN102933579B (sl) |
| AP (1) | AP3170A (sl) |
| AR (1) | AR079636A1 (sl) |
| AU (1) | AU2010332969B2 (sl) |
| BR (1) | BR112012015873B1 (sl) |
| CA (1) | CA2782464C (sl) |
| CL (1) | CL2012001311A1 (sl) |
| CO (1) | CO6650336A2 (sl) |
| CY (1) | CY1115873T1 (sl) |
| DK (1) | DK2513093T3 (sl) |
| EA (1) | EA024397B1 (sl) |
| EC (1) | ECSP12012010A (sl) |
| ES (2) | ES2674275T3 (sl) |
| GE (1) | GEP20146124B (sl) |
| HK (1) | HK1178147A1 (sl) |
| HR (1) | HRP20141143T1 (sl) |
| IL (1) | IL219421A (sl) |
| MA (1) | MA33818B1 (sl) |
| ME (1) | ME01908B (sl) |
| MX (2) | MX346393B (sl) |
| MY (1) | MY160471A (sl) |
| NZ (1) | NZ599770A (sl) |
| PE (1) | PE20121614A1 (sl) |
| PH (1) | PH12012501215A1 (sl) |
| PL (2) | PL3091012T3 (sl) |
| PT (2) | PT2513093E (sl) |
| RS (1) | RS53555B1 (sl) |
| SG (1) | SG181722A1 (sl) |
| SI (1) | SI2513093T1 (sl) |
| TN (1) | TN2012000300A1 (sl) |
| TW (1) | TWI473800B (sl) |
| UY (1) | UY33109A (sl) |
| WO (1) | WO2011073154A1 (sl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| WO2010070032A1 (en) | 2008-12-19 | 2010-06-24 | Boehringer Ingelheim International Gmbh | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
| SI2513093T1 (sl) | 2009-12-17 | 2014-11-28 | Boehringer Ingelheim International Gmbh | Novi CCR2 receptorski antagonisti in njihove uporabe |
| EP2569295B1 (en) | 2010-05-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| JP5786257B2 (ja) * | 2011-06-16 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の選択的ｃｃｒ２拮抗薬 |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| US8877185B2 (en) | 2012-05-10 | 2014-11-04 | Stan S. Sastry | Managing and treating keloids |
| WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
| RU2726206C2 (ru) | 2015-05-21 | 2020-07-09 | Кемосентрикс, Инк. | Модуляторы ccr2 |
| JP6917910B2 (ja) * | 2015-07-02 | 2021-08-11 | セントレクシオン セラピューティクス コーポレイション | （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩 |
| BR112018074452A2 (pt) * | 2016-06-03 | 2019-03-19 | Chemocentryx, Inc. | método de tratamento de fibrose hepática |
| ES2895749T3 (es) * | 2016-06-13 | 2022-02-22 | Chemocentryx Inc | Métodos de tratamiento del cáncer pancreático |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| RU2022102328A (ru) | 2016-11-23 | 2022-04-01 | Хемоцентрикс, Инк. | Способ лечения фокально-сегментарного гломерулосклероза |
| US11304952B2 (en) | 2017-09-25 | 2022-04-19 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor |
| EP3694504A4 (en) | 2017-10-11 | 2021-07-14 | ChemoCentryx, Inc. | TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS |
| MA50423A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| US20210322412A1 (en) * | 2020-04-20 | 2021-10-21 | Centrexion Therapeutics Corporation | Methods and compositions for treating a coronavirus infection |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US568885A (en) * | 1896-10-06 | Can-seaming mechanism | ||
| US213428A (en) * | 1879-03-18 | Improvement in harrow-teeth | ||
| US4032526A (en) | 1975-10-02 | 1977-06-28 | American Cyanamid Company | 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts |
| GB2068961B (en) | 1980-02-13 | 1983-11-30 | Sankyo Co | Quinazoline derivatives |
| DE3517617A1 (de) | 1985-05-15 | 1986-11-20 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel |
| JPS6319745Y2 (sl) | 1985-11-07 | 1988-06-01 | ||
| JPS61165445A (ja) | 1986-01-08 | 1986-07-26 | 株式会社巴組鐵工所 | 振動を減少しうる床構造 |
| US5096916A (en) | 1990-05-07 | 1992-03-17 | Aegis Technology, Inc. | Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline |
| CA2146019A1 (en) | 1992-10-23 | 1994-05-11 | Howard B. Broughton | Dopamine receptor subtype ligands |
| JP3166376B2 (ja) | 1993-02-03 | 2001-05-14 | 松下電器産業株式会社 | 熱利用装置 |
| US5629235A (en) | 1995-07-05 | 1997-05-13 | Winbond Electronics Corporation | Method for forming damage-free buried contact |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| US6437138B1 (en) | 1996-06-06 | 2002-08-20 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| BR9813279B1 (pt) | 1997-10-27 | 2010-11-16 | derivado de homopiperazina, composição farmacêutica, e, uso do derivado de homopiperazina. | |
| US6143892A (en) | 1998-11-20 | 2000-11-07 | G. D. Searle & Co. | Process for making 5-substituted pyrazoles |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| KR100439358B1 (ko) | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ｃｃｒ5 길항제로서 유용한 피페라진 유도체 |
| GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| US20020045613A1 (en) | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| EP1296972B1 (en) | 2000-05-22 | 2009-12-23 | Aventis Pharmaceuticals Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
| BR0114584A (pt) | 2000-10-12 | 2003-08-26 | Boehringer Ingelheim Pharma | Monohidrato cristalino, processos para a sua preparação e sua aplicação para a preparação de um medicamento |
| AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| KR100971616B1 (ko) | 2001-06-22 | 2010-07-22 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| WO2003037271A2 (en) | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| US6806279B2 (en) | 2001-12-17 | 2004-10-19 | Sunesis Pharmaceuticals, Inc. | Small-molecule inhibitors of interleukin-2 |
| CA2474214A1 (en) | 2002-02-05 | 2003-08-14 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
| JP2003240776A (ja) | 2002-02-13 | 2003-08-27 | Horiba Ltd | クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置 |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US7205304B2 (en) | 2002-03-13 | 2007-04-17 | Janssen Pharmaceutica N.V. | Sulfonyl-Derivatives as novel inhibitors of histone deacetylase |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| US20050245537A1 (en) | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| SI1501507T1 (sl) | 2002-04-29 | 2008-12-31 | Merck & Co Inc | Tetrahidropiranil ciklopentil tetrahidropiridopiridin modulatorji s kemokinsko receptorsko aktivnostjo |
| CA2488402A1 (en) | 2002-06-05 | 2003-12-18 | Pharmacia Corporation | Pyrazole-derivatives as p38 kinase inhibitors |
| AU2003270199A1 (en) | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| US20040147561A1 (en) | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
| WO2004074438A2 (en) * | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| MXPA05009661A (es) | 2003-03-12 | 2006-03-08 | Kudos Pharm Ltd | Derivados de ftalazinona. |
| US7592347B2 (en) | 2003-04-23 | 2009-09-22 | Glaxo Group Limited | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases |
| FR2854158B1 (fr) | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| ES2291913T3 (es) | 2003-07-18 | 2008-03-01 | Glaxo Group Limited | Piperidinas sustituidas como ligandos del receptor h3 de la histamina. |
| JP4680903B2 (ja) | 2003-07-29 | 2011-05-11 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | ピリダジニル−ピペラジンおよびそれらのヒスタミンｈ３受容体リガンドとしての使用 |
| AP2439A (en) | 2003-12-18 | 2012-08-31 | Incyte Corp | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| US7435830B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| JP2007531753A (ja) | 2004-03-31 | 2007-11-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非イミダゾール系複素環式化合物 |
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006001958A2 (en) | 2004-05-21 | 2006-01-05 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| KR101194622B1 (ko) | 2004-06-02 | 2012-10-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 접합 헤테로시클릭 화합물 |
| FR2871157A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Produits biaryl aromatiques, compositions les contenant et utilisation |
| AU2005267289A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| BRPI0512623A (pt) | 2004-06-25 | 2008-03-25 | Janssen Phamaceutica N V | sal quaternário antagonista de ccr2 |
| CN1976707A (zh) * | 2004-06-28 | 2007-06-06 | 因赛特公司 | 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类 |
| UA83311C2 (en) * | 2004-06-28 | 2008-06-25 | Инсайт Корпорейшн | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| WO2006034440A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| JP5337375B2 (ja) | 2004-11-02 | 2013-11-06 | ノースウェスタン ユニバーシティ | ピリダジン化合物、組成物および方法 |
| PA8653301A1 (es) | 2004-11-22 | 2006-11-09 | Incyte Corp Incyte Corp | Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin |
| DE102004061751A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Cyanoguanidin-substituierte Pyrazoline |
| SI1849773T1 (sl) | 2005-02-17 | 2013-12-31 | Astellas Pharma Inc. | Piperazinski derivati za zdravljenje urinske inkontinence in bolečine |
| WO2006113261A2 (en) | 2005-04-14 | 2006-10-26 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| WO2006113140A2 (en) | 2005-04-15 | 2006-10-26 | Elan Pharmaceuticals, Inc. | Novel compounds useful for bradykinin b1 receptor antagonism |
| US20070078135A1 (en) | 2005-04-18 | 2007-04-05 | Neurogen Corporation | Substituted heteroaryl CB1 antagonists |
| EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007003604A2 (en) | 2005-07-04 | 2007-01-11 | Novo Nordisk A/S | Hists1mine h3 receptor antagonists |
| EP1909797A4 (en) | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
| GB0517184D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| TW200800999A (en) * | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| NZ566862A (en) | 2005-09-27 | 2010-12-24 | Irm Llc | Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20100016289A1 (en) | 2005-11-01 | 2010-01-21 | Kevin Sprott | Compounds Useful as Antagonists of CCR2 |
| RU2008123388A (ru) | 2005-11-14 | 2009-12-27 | Айрм Ллк (Bm) | Соединения и композиции в качестве модуляторов lxr |
| WO2007063934A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 脂環式複素環化合物 |
| CA2627630A1 (en) | 2005-12-20 | 2007-06-28 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptors |
| IL172838A (en) | 2005-12-27 | 2010-06-16 | Joma Int As | Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby |
| WO2007084868A2 (en) | 2006-01-17 | 2007-07-26 | Kalypsys, Inc. | Treatment of disorders by activation of the unfolded protein response |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| EP1989185B8 (en) | 2006-02-28 | 2013-06-26 | Dart NeuroScience LLC | Therapeutic compounds |
| CA2643066A1 (en) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| JP2009533435A (ja) | 2006-04-11 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | ジアリール置換アルカン |
| US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| EP2015751A2 (en) | 2006-04-28 | 2009-01-21 | Northwestern University | Salts of pyridazine compounds |
| DE602007004618D1 (de) | 2006-06-22 | 2010-03-18 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren |
| US7935715B2 (en) | 2006-07-28 | 2011-05-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| GB0617575D0 (en) | 2006-09-06 | 2006-10-18 | Syngenta Ltd | Herbicidal compounds and compositions |
| AU2007300295A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| CA2669917A1 (en) | 2006-11-17 | 2008-05-22 | Dawn M. George | Aminopyrrolidines as chemokine receptor antagonists |
| WO2008083027A1 (en) | 2006-12-28 | 2008-07-10 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
| AU2008215948A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of AD and related conditions |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| FR2915552B1 (fr) | 2007-04-27 | 2009-11-06 | Technip France | Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux. |
| WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| CN101687844B (zh) | 2007-07-02 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr2受体拮抗剂的咪唑衍生物 |
| US7977358B2 (en) | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| ATE520682T1 (de) | 2007-08-22 | 2011-09-15 | Irm Llc | 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren |
| CN101801952A (zh) | 2007-10-01 | 2010-08-11 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物 |
| MX2010003868A (es) | 2007-10-09 | 2010-04-27 | Hoffmann La Roche | Cis-imidazolinas quirales. |
| EP2200470A4 (en) | 2007-10-12 | 2013-11-20 | Jong O Whang | SNAIL INSTRUMENT FOR SHOES |
| WO2009067406A1 (en) | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| US8829006B2 (en) | 2007-11-22 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Compounds |
| EP2062889A1 (de) | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
| CA2725657A1 (en) | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Novel heteroaryl carboxamide derivatives |
| JP5693452B2 (ja) | 2008-08-04 | 2015-04-01 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法 |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| NZ591226A (en) | 2008-09-02 | 2012-11-30 | Boehringer Ingelheim Int | Benzoic acid amides, production thereof, and use thereof as medicaments |
| EP2342200B1 (en) | 2008-09-25 | 2013-01-23 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
| WO2010070032A1 (en) | 2008-12-19 | 2010-06-24 | Boehringer Ingelheim International Gmbh | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
| CA2750635A1 (en) | 2009-02-23 | 2010-08-26 | Merck Canada Inc. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| SI2513093T1 (sl) | 2009-12-17 | 2014-11-28 | Boehringer Ingelheim International Gmbh | Novi CCR2 receptorski antagonisti in njihove uporabe |
| WO2011073155A1 (en) | 2009-12-17 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Novel antagonists for ccr2 and uses thereof |
| EP2542539B1 (en) | 2010-03-05 | 2014-02-26 | Boehringer Ingelheim International GmbH | Tetrazole compounds which selectively modulate the cb2 receptor |
| EP2569295B1 (en) | 2010-05-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| JP5786257B2 (ja) | 2011-06-16 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の選択的ｃｃｒ２拮抗薬 |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| JP6229575B2 (ja) | 2014-03-31 | 2017-11-15 | 京セラドキュメントソリューションズ株式会社 | 画像処理装置 |
| JP6917910B2 (ja) * | 2015-07-02 | 2021-08-11 | セントレクシオン セラピューティクス コーポレイション | （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩 |
-
2010
- 2010-12-13 SI SI201030770T patent/SI2513093T1/sl unknown
- 2010-12-13 PE PE2012000827A patent/PE20121614A1/es active IP Right Grant
- 2010-12-13 WO PCT/EP2010/069549 patent/WO2011073154A1/en active Application Filing
- 2010-12-13 EP EP14177921.5A patent/EP2813503B1/en not_active Not-in-force
- 2010-12-13 PH PH1/2012/501215A patent/PH12012501215A1/en unknown
- 2010-12-13 ES ES16157027.0T patent/ES2674275T3/es active Active
- 2010-12-13 AU AU2010332969A patent/AU2010332969B2/en active Active
- 2010-12-13 JP JP2012543667A patent/JP5632014B2/ja active Active
- 2010-12-13 NZ NZ599770A patent/NZ599770A/en not_active IP Right Cessation
- 2010-12-13 EP EP16157027.0A patent/EP3091012B1/en active Active
- 2010-12-13 ES ES10796336.5T patent/ES2524829T3/es active Active
- 2010-12-13 PT PT107963365T patent/PT2513093E/pt unknown
- 2010-12-13 DK DK10796336.5T patent/DK2513093T3/da active
- 2010-12-13 MX MX2013008863A patent/MX346393B/es unknown
- 2010-12-13 EA EA201200876A patent/EA024397B1/ru not_active IP Right Cessation
- 2010-12-13 RS RS20140526A patent/RS53555B1/en unknown
- 2010-12-13 CN CN201080057415.2A patent/CN102933579B/zh active Active
- 2010-12-13 ME MEP-2014-106A patent/ME01908B/me unknown
- 2010-12-13 GE GEAP201012789A patent/GEP20146124B/en unknown
- 2010-12-13 PT PT161570270T patent/PT3091012T/pt unknown
- 2010-12-13 EP EP10796336.5A patent/EP2513093B1/en active Active
- 2010-12-13 KR KR1020127014412A patent/KR101530234B1/ko active IP Right Grant
- 2010-12-13 SG SG2012044129A patent/SG181722A1/en unknown
- 2010-12-13 PL PL16157027T patent/PL3091012T3/pl unknown
- 2010-12-13 BR BR112012015873-2A patent/BR112012015873B1/pt not_active IP Right Cessation
- 2010-12-13 CA CA2782464A patent/CA2782464C/en active Active
- 2010-12-13 AP AP2012006276A patent/AP3170A/xx active
- 2010-12-13 MY MYPI2012002736A patent/MY160471A/en unknown
- 2010-12-13 MX MX2012006964A patent/MX2012006964A/es active IP Right Grant
- 2010-12-13 PL PL10796336T patent/PL2513093T3/pl unknown
- 2010-12-16 US US12/969,745 patent/US8765949B2/en active Active
- 2010-12-16 TW TW99144272A patent/TWI473800B/zh active
- 2010-12-16 UY UY33109A patent/UY33109A/es not_active Application Discontinuation
- 2010-12-16 AR ARP100104699A patent/AR079636A1/es not_active Application Discontinuation
-
2012
- 2012-04-25 IL IL219421A patent/IL219421A/en active IP Right Grant
- 2012-05-18 CL CL2012001311A patent/CL2012001311A1/es unknown
- 2012-06-13 TN TNP2012000300A patent/TN2012000300A1/en unknown
- 2012-06-14 MA MA34961A patent/MA33818B1/fr unknown
- 2012-06-15 CO CO12101565A patent/CO6650336A2/es active IP Right Grant
- 2012-06-28 EC ECSP12012010 patent/ECSP12012010A/es unknown
-
2013
- 2013-04-26 HK HK13105048.6A patent/HK1178147A1/xx unknown
-
2014
- 2014-04-24 US US14/260,552 patent/US9670222B2/en active Active
- 2014-11-12 CY CY20141100939T patent/CY1115873T1/el unknown
- 2014-11-25 HR HRP20141143AT patent/HRP20141143T1/hr unknown
-
2017
- 2017-05-26 US US15/606,749 patent/US10196402B2/en active Active
-
2018
- 2018-12-27 US US16/233,315 patent/US11046706B2/en active Active
-
2021
- 2021-06-11 US US17/345,110 patent/US11731981B2/en active Active
-
2023
- 2023-07-31 US US18/362,028 patent/US12209094B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3170A (en) | New CCR2 receptor antagonists and uses thereof | |
| HUS2200033I1 (hu) | CGRP receptor antagonisták | |
| ZA201202029B (en) | Androgen receptor antagonists and uses thereof | |
| IL229507A (en) | External opioid receptor antagonists and their uses | |
| ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
| HK1203980A1 (en) | Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb | |
| IL218502A0 (en) | Actriib antagonists and dosing and uses thereof | |
| ZA201103156B (en) | Isonicotinamide orexin receptor antagonists | |
| SG10201404662YA (en) | Dp2 antagonist and uses thereof | |
| PL2137191T3 (pl) | Antagoniści obwodowego receptora opioidowego i ich zastosowania | |
| HRP20150661T1 (en) | Peripheral opioid receptor and antagonists and uses thereof | |
| ZA201105056B (en) | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 | |
| IL217526A0 (en) | Carbocyclic glyt1 receptor antagonists | |
| IL217965A0 (en) | Bicyclic heterocycles and their use as ccr2 receptor antagonists | |
| GB0701632D0 (en) | MET receptor antagonists | |
| GB0900756D0 (en) | EP4 Receptor antagonists | |
| GB0901836D0 (en) | EP4 receptor antagonists | |
| GB0900755D0 (en) | Ep4 receptor antagonists | |
| GB0900754D0 (en) | EP4 Receptor antagonists |
